MedPath

Steminent Biotherapeutics Inc.

Steminent Biotherapeutics Inc. logo
🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

Safety Study of Stemchymal® in Acute Liver Failure

Phase 1
Withdrawn
Conditions
Acute Liver Failure
Steminent
Stem Cells
Adult Stem Cells
Acute-On-Chronic Liver Failure
First Posted Date
2018-08-14
Last Posted Date
2022-10-28
Lead Sponsor
Steminent Biotherapeutics Inc.
Registration Number
NCT03629015
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee

Phase 1
Completed
Conditions
Osteoarthritis Knee
Interventions
Drug: Adipose-Derived Mesenchymal Stem Cells
First Posted Date
2015-09-09
Last Posted Date
2022-10-28
Lead Sponsor
Steminent Biotherapeutics Inc.
Target Recruit Count
4
Registration Number
NCT02544802
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia

Phase 2
Completed
Conditions
Cerebellar Ataxia
First Posted Date
2015-09-04
Last Posted Date
2022-10-27
Lead Sponsor
Steminent Biotherapeutics Inc.
Target Recruit Count
56
Registration Number
NCT02540655
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.